E-ISSN: 2148-094X ISSN: 2619-9793
Evaluation of Gastroenteropancreatic Neuroendocrine Tumors for Ki 67, p16 and Cyclin D1 Expression
PDF
Cite
Share
Request
Original Article
VOLUME: 12 ISSUE: 3
P: 105-112
September 2011

Evaluation of Gastroenteropancreatic Neuroendocrine Tumors for Ki 67, p16 and Cyclin D1 Expression

İstanbul Med J 2011;12(3):105-112
DOI: 10.5505/1304.8503.2011.43531
Gülzade ÖZYALVAÇLI 1
Esra PAŞAOĞLU 2
Zuhal GÜCİN 3
Kemal BEHZATOĞLU 2
Feray GÜNVER 2
Erol Rüştü BOZKURT 2
1. Osmaniye State Hospital, Osmaniye
2. Istanbul Education and Research Hospital, Istanbul
3. Bezmialem Vakif University Medical School, Istanbul
No information available.
No information available
Received Date: 14.04.2011
Accepted Date: 05.07.2011
PDF
Cite
Share
Request

ABSTRACT

Objectives:

The aim of this study was to examine the roles of p16/cyclin D1 and Ki 67 proliferation index in gastroenteropancreatic neuroendocrine tumors (GEPNETs), which were classified by the World Health Organization (WHO).

Methods:

A series of 41 cases of GEPNETs including 16 well-differentiated endocrine tumors (WDET), 17 welldifferentiated endocrine carcinomas (WDEC) and 8 poorly differentiated endocrine carcinomas (PDEC) were searched for p16, cyclin D1 and Ki 67 expression.

Results:

Overexpression of p16 and cyclin D1 was observed in 8 (50%) and 8 (50%) of 16 WDET cases, 12 (70%) and 5 (29%) of 17 WDEC cases and 5 (63%) and 5 (63%) of 8 PDEC cases. Low Ki 67 index (≤2%) was found in 15 (94%) of WDETs, 13 (76%) of WDECs and none of PDECs.

Conclusion:

Ki 67 index was low in WDECs as in WDETs. High Ki 67 index (>10%) is related to poor prognosis, but low proliferation activity is not an indicator of benign behavior. There were no significant differences between the tumor groups with respect to p16 and cyclin D1 expression in our study. More objective results can be obtained in such studies that include retinoblastoma protein and analyze all of the components of the Rb pathway.